Insights Into Medtronic (MDT) Q1: Wall Street Projections for Key Metrics

The upcoming report from Medtronic (MDT) is expected to reveal quarterly earnings of $1.39 per share, indicating an increase of 10.3% compared to the year-ago period. Analysts forecast revenues of $9.47 billion, representing an increase of 10.4% year over year.

The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.

While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.

Given this perspective, it's time to examine the average forecasts of specific Medtronic metrics that are routinely monitored and predicted by Wall Street analysts.

The average prediction of analysts places 'Net Sales- World Wide Revenue- Other' at $19.75 million. The estimate indicates a change of -72.6% from the prior-year quarter.

It is projected by analysts that the 'Net Sales- World Wide Revenue- Neuroscience' will reach $2.67 billion. The estimate suggests a change of +10.7% year over year.

The combined assessment of analysts suggests that 'Net Sales- World Wide Revenue- Cardiovascular' will likely reach $3.78 billion. The estimate suggests a change of +15.2% year over year.

Analysts forecast 'Net Sales- World Wide Revenue- Medical Surgical' to reach $2.24 billion. The estimate points to a change of +7.6% from the year-ago quarter.

Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Diabetes' should arrive at $829.71 million. The estimate indicates a year-over-year change of +15.1%.

The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Cardiovascular- Structural Heart & Aortic' of $993.59 million. The estimate points to a change of +6.8% from the year-ago quarter.

According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Medical Surgical- Surgical & Endoscopy' should come in at $1.72 billion. The estimate suggests a change of +6.8% year over year.

Analysts expect 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' to come in at $567.41 million. The estimate points to a change of +12.6% from the year-ago quarter.

Analysts predict that the 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' will reach $1.34 billion. The estimate indicates a change of +10.7% from the prior-year quarter.

Analysts' assessment points toward 'Net Sales- World Wide Revenue- Cardiovascular- Coronary & Peripheral Vascular' reaching $714.07 million. The estimate points to a change of +11.1% from the year-ago quarter.

The consensus estimate for 'Net Sales- World Wide Revenue- Neuroscience- Specialty Therapies' stands at $769.31 million. The estimate points to a change of +9.6% from the year-ago quarter.

The consensus among analysts is that 'Net Sales- U.S. Revenue' will reach $4.82 billion. The estimate indicates a year-over-year change of +14.1%.

Shares of Medtronic have demonstrated returns of +5.1% over the past month compared to the Zacks S&P 500 composite's +3.7% change. With a Zacks Rank #3 (Hold), MDT is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research